www.biorxiv.org/content/10.6...
www.biorxiv.org/content/10.6...
In this issue of Blood, the second paper of my PhD is published. We show that MECOM, a key HSC TF, maintains stem cell state by preventing change through repression of CEBPA. #hemesky ashpublications.org/blood/articl...
In this issue of Blood, the second paper of my PhD is published. We show that MECOM, a key HSC TF, maintains stem cell state by preventing change through repression of CEBPA. #hemesky ashpublications.org/blood/articl...
You got it:
currentprotocols.onlinelibrary.wiley.com/doi/10.1002/...
You got it:
currentprotocols.onlinelibrary.wiley.com/doi/10.1002/...
#EHA2025.
#outsmartingcancer
@oncodeinstitute.bsky.social
#outsmartingcancer
@oncodeinstitute.bsky.social
key point: 2/3rds of TF isos differ in properties like DNA binding & transcriptional activity
many are "negative regulators" & misexpressed in cancer
www.sciencedirect.com/science/arti...
@dpastoors.bsky.social gave nice talk on p300&CBP regulating enhancer activity in AML which was awarded with the Best Presentation Award! 🤩🥳
#Hemesky
Publications from 2025 are shared more on Bluesky than on X/Twitter.
Publications from 2025 are shared more on Bluesky than on X/Twitter.